M Williams
#150,865
Most Influential Person Now
Researcher
M Williams's AcademicInfluence.com Rankings
M Williamsengineering Degrees
Engineering
#6091
World Rank
#7395
Historical Rank
Electrical Engineering
#1767
World Rank
#1866
Historical Rank
M Williamscomputer-science Degrees
Computer Science
#7929
World Rank
#8345
Historical Rank
Computational Linguistics
#1680
World Rank
#1698
Historical Rank
Machine Learning
#3105
World Rank
#3144
Historical Rank
Artificial Intelligence
#3406
World Rank
#3456
Historical Rank
Download Badge
Engineering Computer Science
M Williams's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is M Williams Influential?
(Suggest an Edit or Addition)M Williams's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nomenclature and classification of purinoceptors. (1994) (1631)
- [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. (1989) (511)
- A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat (2002) (455)
- Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. (1992) (425)
- The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. (1990) (392)
- Towards a revised nomenclature for P1 and P2 receptors. (1997) (361)
- Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. (1989) (357)
- Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. (1998) (349)
- Neuronal nicotinic acetylcholine receptors as novel drug targets. (2000) (299)
- P2 purinergic receptors: modulation of cell function and therapeutic potential. (2000) (294)
- Purine receptors in mammalian tissues: pharmacology and functional significance. (1987) (294)
- CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. (1989) (253)
- CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. (1988) (233)
- Binding of [3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to rat brain membranes: a selective, high-affinity ligand for N-methyl-D-aspartate receptors. (1987) (200)
- Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. (1996) (197)
- [3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. (1991) (192)
- Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists. (1986) (175)
- Purinergic and pyrimidinergic receptors as potential drug targets. (2000) (174)
- Adenosine and Adenosine Receptors (1990) (170)
- Characterization of the binding of [3H]‐CGS 19755: a novel N‐methyl‐d‐aspartate antagonist with nanomolar affinity in rat brain (1988) (164)
- Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. (1987) (150)
- A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. (1992) (149)
- Biochemical characterization of putative central purinergic receptors by using 2-chloro[3H]adenosine, a stable analog of adenosine. (1980) (147)
- Restoration of shock‐suppressed behavior by treatment with (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo[a, d]cyclohepten‐5, 10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties (1982) (139)
- CHARACTERIZATION OF THE BINDING OF [3H]MUSCIMOL, A POTENT γ‐AMINOBUTYRIC ACID AGONIST, TO RAT BRAIN SYNAPTOSOMAL MEMBRANES USING A FILTRATION ASSAY (1979) (136)
- Adenosine: The prototypic neuromodulator (1989) (123)
- A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand (1996) (120)
- Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist. (1987) (115)
- Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization (2003) (113)
- Serotonin-releasing effects of substituted piperazines in vitro. (1984) (109)
- Enhancement of the binding of 3H-diazepam to rat brain membranes in vitro by SQ 20009, A novel anxiolytic, gamma-aminobutyric acid (GABA) and muscimol. (1979) (106)
- Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. (2000) (106)
- Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. (1998) (105)
- ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. (2000) (103)
- Binding of the nicotinic cholinergic antagonist, dihydro-beta- erythroidine, to rat brain tissue (1984) (103)
- 2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands. (1990) (100)
- Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects (2003) (99)
- ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. (1998) (96)
- Purinoceptor nomenclature: A status report (1993) (93)
- Autoradiographic characterization of high-affinity adenosine A2 receptors in the rat brain (1989) (93)
- Quantitative autoradiographic localization of NMDA receptors in rat brain using [3H]CPP: comparison with [3H]TCP binding sites. (1987) (88)
- Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. (1994) (87)
- Challenges in the Search for Drugs to Treat Central Nervous System Disorders (2009) (85)
- ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. (2000) (85)
- ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. (1998) (82)
- Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. (1989) (79)
- Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. (1984) (79)
- ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. (1997) (73)
- Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rat brain: evidence for multiple affinity states of the phencyclidine/N-methyl-D-aspartate receptor complex. (1987) (71)
- Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor.. (2001) (69)
- Adenosine — a selective neuromodulator in the mammalian CNS? (1984) (68)
- Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. (2004) (68)
- ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. (1996) (66)
- Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. (1998) (65)
- 4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity. (1989) (65)
- Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist. (1987) (64)
- Adenosine A1 receptors in mammalian brain: Species differences in their interactions with agonists and antagonists (1986) (64)
- Enhancement of in vitro binding and some of the pharmacological properties of diazepam by a novel anthelmintic agent, Avermectin B1a. (1979) (63)
- Species differences in high‐affinity adenosine A2 binding sites in striatal membranes from mammalian brain (1988) (63)
- (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431). (1995) (63)
- Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. (2011) (61)
- The novel anticonvulsant MK-801 interacts with central phencyclidine recognition sites in rat brain. (1987) (60)
- Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. (1981) (60)
- Adenosine antagonists as potential therapeutic agents (1988) (56)
- Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. (2006) (56)
- A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists. (1982) (55)
- Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists. (1984) (55)
- Characterization of quisqualate recognition sites in rat brain tissue usingDl-[3H]α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay (1987) (55)
- CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities (2012) (54)
- Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. (1997) (53)
- Novel therapeutics acting via purine receptors. (1991) (53)
- Molecular aspects of the action of benzodiazepine and nonbenzodiazepine anxiolytics: A hypothetical allosteric model of the benzodiazepine receptor complex (1984) (50)
- The epidemiology of lung cancer. (2001) (49)
- Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis. (2001) (47)
- Interaction of putative anxiolytic agents with central adenosine receptors. (1981) (46)
- Neurotensin effects on brain dopaminergic systems (1982) (45)
- Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome. (1988) (44)
- Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties. (2002) (42)
- The effect of ABT‐702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury (2001) (41)
- A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. (1996) (40)
- (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. I. In Vitro Characterization (2002) (39)
- The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594 (1998) (39)
- Agonist derived molecular probes for A2 adenosine receptors (1989) (37)
- The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain. (2000) (37)
- Characterization of Adenosine Receptors in the PC 12 Pheochromocytoma Cell Line Using Radioligand Binding: Evidence for A‐2 Selectivity (1987) (37)
- Defining the role of pharmacology in the emerging world of translational research. (2009) (36)
- Adenosine in Central Nervous System Function (1990) (36)
- Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue (1986) (35)
- Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. (1982) (34)
- Adenosine and Cardiovascular Function (1990) (34)
- The N-methyl-D-aspartate receptor complex. (1988) (33)
- P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptors (1997) (33)
- Purinergic drugs: Opportunities in the 1990s (1993) (32)
- Characterization of [3H]ABT-418: a novel cholinergic channel ligand. (1995) (32)
- Combination therapy with nucleoside analogs and alkylating agents. (1994) (32)
- RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist. (1983) (31)
- Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor. (1999) (31)
- Purine Nucleosides and Nucleotides as Central Nervous System Modulators (1990) (30)
- Interaction of taurine and β-alanine with central nervous system neurotransmitter receptors (1980) (30)
- [3H]A-317491, a Novel High-Affinity Non-Nucleotide Antagonist That Specifically Labels Human P2X2/3 and P2X3 Receptors (2004) (30)
- Correlation between binding affinities for brain A1 and A2 receptors of adenosine agonists and antagonists and their effects on heart rate and coronary vascular tone. (1988) (29)
- High affinity binding of 2-chloroadenosine to rat brain synaptic membranes. (1980) (28)
- Mammalian Central Adenosine Receptors (1984) (28)
- Differences in adenosine A-1 and A-2 receptor density revealed by autoradiography in methylxanthine-sensitive and insensitive mice (1988) (27)
- Further evidence for selective antagonism of taurine by 6-aminomethyl-3-methyl-4H-1,2,4-benzothiadiazine-1,1-dioxide (1981) (27)
- Preparation of some 10-[3-(dimethylamino)-1-propyl]-10H-pyrazino[2,3-b][1,4] benzothiazines as potential neuroleptics. (1983) (25)
- Synthesis, assignment of absolute configuration, and receptor binding studies relevant to the neuroleptic activities of a series of chiral 3-substituted cyproheptadine atropisomers. (1979) (24)
- Interaction of the putative dopamine autoreceptor agonists, 3-PPP and TL-99, with the dopamine-sensitive adenylate cyclase of carp retina. (1982) (24)
- [3H]Cyclohexyladenosine binding in rat brain: A pharmacological analysis using quantitative autoradiography (1986) (24)
- Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo. (1985) (24)
- Ivermectin Interactions with Benzodiazepine Receptors in Rat Cortex and Cerebellum In Vitro (1984) (23)
- Synthesis, opioid receptor binding profile, and antinociceptive activity of 1-azaspiro[4.5]decan-10-yl amides. (1989) (22)
- Potential antitumor agents: a cytotoxic cardenolide from Coronilla varia L. (1976) (22)
- Challenges in developing P2 purinoceptor-based therapeutics. (2007) (22)
- Synthesis and receptor binding studies relevant to the neuroleptic activities of some 1-methyl-4-piperidylidene-9-substituted-pyrrolo[2,1-b][3]benzazepine derivatives. (1983) (21)
- Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene. (1982) (21)
- Antagonism of l-5-hydroxytryptophan-induced head twitching in rats by lisuride: A mixed 5-hydroxytryptamine agonist-antagonist? (1985) (20)
- Selectivity of cyproheptadine as assessed by radioligand binding (1982) (20)
- Interaction of avermectins with [3H]beta-carboline-3-carboxylate ethyl ester and [3H]diazepam binding sites in rat brain cortical membranes. (1982) (20)
- Inhibition of postsynaptic dopamine-sensitive adenylate cyclase in carp retina by the putative dopamine autoreceptor agonist, 3-PPP. (1982) (19)
- Chronic in vivo treatment with desmethylimipramine and mianserin does not alter adenosine A-1 radioligand binding in rat cortex (1983) (19)
- Interaction of 2-phenylaminoadenosine (CV 1808) with adenosine systems in rat tissues. (1982) (19)
- Benzodiazepine interactions with central thyroid-releasing hormone binding sites: characterization and physiological significance. (1986) (18)
- CGS 20625, a novel pyrazolopyridine anxiolytic. (1989) (18)
- 2-chloroadenosine inhibits brain acetylcholine turnover in vivo. (1981) (17)
- Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1, receptor subtypes in the rat brain (1988) (17)
- Benzofuro[2,3-c]pyridin-6-ols: synthesis, affinity for opioid-receptor subtypes, and antinociceptive activity. (1989) (17)
- Bioactive conformation of 1-arylpiperazines at central serotonin receptors. (1985) (16)
- Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework. (1999) (15)
- The Discovery of Quinoxaline-Based Metathesis Catalysts from Synthesis of Grazoprevir (MK-5172). (2016) (15)
- Effects of Purine Nucleotides on the Binding of [3H]Cyclopentyladenosine to Adenosine A‐l Receptors in Rat Brain Membranes (1986) (15)
- Adenosine: Some Therapeutic Applications and Prospects (1995) (14)
- The novel N‐Methyl‐D‐Aspartate (NMDA) antagonist CGS 19755 prevents ischemia‐induced reductions of adenosine A1, NMDA, and PCP receptors in gerbil brain (1988) (14)
- Antihypertensive beta-adrenergic blocking agents: N-aralkyl analogues of 2-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyanopyridine. (1983) (14)
- Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. (2010) (14)
- Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex. (1991) (14)
- Effect of Fiduxosin, an Antagonist Selective for α1A- and α1D-Adrenoceptors, on Intraurethral and Arterial Pressure Responses in Conscious Dogs (2002) (14)
- Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity. (1983) (14)
- Muscarinic, benzodiazepine, gaba, chloride channel and other binding sites in frontal cortex in hepatic coma in man (1987) (14)
- Nicotinic receptors in mammalian brain (1984) (13)
- Potent dopamine agonist activity of a novel ergoline, 6-ethyl-9-oxaergoline (EOE). (1982) (13)
- Biochemical characterization of the antagonist actions of the xanthines, PACPX (1,3-dipropyl-8(2-amino-4-chloro)phenylxanthine) and 8-PT (8-phenyltheophylline) at adenosine A1 and A2 receptors in rat brain tissue. (1987) (13)
- Purines: from premise to promise. (2000) (13)
- Effects of deanol, choline and its metabolites on binding of [3H]quinuclidinyl benzilate to rat brain membranes. (1979) (13)
- Adenosine receptors in the mammalian central nervous system (1983) (13)
- Radioligand Binding Assays for Adenosine Receptors (1990) (13)
- ABT-866, a novel α1A-adrenoceptor agonist with antagonist properties at the α1B- and α1D-adrenoceptor subtypes (2002) (13)
- Interaction of the benzodiazepine antagonists, CGS 8216 and Ro 15-1788, with central adenosine A-1 receptors. (1982) (12)
- Chapter 21: The Receptor: From Concept to Function (1986) (12)
- Binding of [3H]cyclohexyladenosine to adenosine recognition sites in guinea pig ileal membranes: Comparison with binding in brain membranes (1985) (12)
- Autoradiographic localization of adenosine A1 receptors in rat brain using [3H]XCC, a functionalized congener of 1,3-dipropylxanthine (1987) (12)
- Chapter 4 Excitatory Amino Acids and Mammalian CNS Function (1987) (11)
- ABT‐089 [3‐(2(S)‐pyrrolidinylmethoxy)‐2‐methyl‐pyridine]: An orally effective cholinergic channel modulator with potential once‐a‐day dosing and cardiovascular safety (1997) (10)
- PURINERGIC NEUROTRANSMISSION (2001) (10)
- 2H-[1]benzopyrano[3,4-b]pyridines: synthesis and activity at central monoamine receptors. (1989) (9)
- Purinergic Pharmaceuticals for the 1990s (1991) (9)
- Stereospecific antidopaminergic and anticholinergic actions of the enantiomers of (+/-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene) piperidine (CTC), a derivative of cyproheptadine. (1979) (9)
- (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. II. In Vivo Characterization (2002) (9)
- Pharmacological characterization of A‐131701, a novel α1‐adrenoceptor antagonist selective for α1A‐ and α1D‐compared to α1B‐adrenoceptors (1998) (9)
- Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors (nAChR′s). (1996) (8)
- P2-Purinoceptors: Advances and therapeutic opportunities. (1995) (8)
- 3-(1′-Cyclobutylspiro[4H-1,3-benzodioxine-2,4′-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist (2016) (8)
- Alzheimer's disease and related dementias: prospects for treatment. (1997) (8)
- Adenosine Receptors as Drug Targets: Fulfilling the Promise? (1990) (8)
- Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. II. Effects on macromolecular synthesis in cell culture and evidence for alkylating activity. (1976) (8)
- Interaction of 2‐[β‐(4‐hydroxyphenyl)ethylaminomethyl]tetralone (BE‐2254: ‘HEAT’) with catecholamine receptors in rat brain membranes (1978) (8)
- Effect of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cells. (1991) (8)
- N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. (2002) (7)
- Nicotinic acetylcholine receptors as therapeutic targets: emerging frontiers in basic research and clinical science - editorial comments. (2007) (7)
- Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes. (1982) (7)
- Receptors as Drug Targets (1998) (7)
- Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. (2001) (7)
- Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. (2002) (7)
- The neuropharmacology of a novel gamma-aminobutyric acid analog, kojic amine. (1979) (7)
- 2.11 – Enabling Technologies in Drug Discovery: The Technical and Cultural Integration of the New with the Old (2007) (6)
- Cholinergic channel activators: novel opportunities for the treatment of CNS disorders. (1995) (6)
- ABT-866, a novel alpha(1A)-adrenoceptor agonist with antagonist properties at the alpha(1B)- and alpha(1D)-adrenoceptor subtypes. (2002) (5)
- A‐80426, a potent and selective α2‐adrenoceptor antagonist with serotonin uptake‐blocking activity and putative antidepressant‐like effects: II. Pharmacology profile (1995) (5)
- Protein phosphorylation in the mammalian nervous system (1979) (5)
- Purinoceptor Nomenclature: Challenges for the Future (1995) (5)
- Biochemical characterization of the enantiomers of the novel ergoline dopamine agonist 6‐ethyl‐9‐oxaergoline (EOE) (1983) (5)
- Aminopyridazine muscarinic agonist, SR 95639A, is a functional M2 receptor antagonist in rat brain (1991) (5)
- ABT-418: A Novel Cholinergic Channel Activator (ChCA) for the Potential Treatment of Alzheimer’s Disease (1994) (4)
- Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface (2014) (4)
- CHAPTER 3. P2 PURINOCEPTORS : A FAMILY OF NOVEL THERAPEUTIC TARGETS (1996) (4)
- Chapter 1. Adenosine as a Neuromodulator in the Mammalian Central Nervous System (1983) (4)
- Central phencyclidine (PCP) receptor binding is glutamate dependent: evidence for a PCP/excitatory amino acid receptor (EAAR) complex (1986) (4)
- Cervical, Ovarian, and Uterine Cancer: Advancing Awareness, Choices, and Survival (1996) (3)
- Biochemical characterization of putative central purinergic receptors by using 2-chloro [ 3 H ] adenosine , a stable analog of adenosine ( radioligand binding / central neuromodulators / methylxanthines ) (3)
- A‐80426, a potent α2‐adrenoceptor antagonist with serotonin uptake blocking activity and putative antidepressant‐like effects: I. Biochemical profile (1995) (3)
- Purinergic Neurotransmission: An Historical Background (2001) (3)
- Clinical Opportunities in Purinergic Neuromodulation (2001) (3)
- Pancreatic cancer: an epidemiologic approach and model. (1981) (3)
- ABT — 418, a Novel Nicotinic Agonist (1994) (2)
- ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action (1997) (2)
- Interaction of 2-[beta-(4-hydroxyphenyl)ethylaminomethyl]tertralone (BE-2254: 'HEAT') with catecholamine receptors in rat brain membranes. (1978) (2)
- Biochemical characterization of neurotransmitter receptors in the central nervous system (1980) (2)
- L-646,462, a cyproheptadine-related antagonist of dopamine and serotonin with selectivity for peripheral systems. (1984) (2)
- Sub-chronic administration of ethanol to mice does not modify the inhibitory effects of dieldrin, abamectin and the dihydropyrazole RH-3421 at their respective sites of action in the nervous system. (1993) (2)
- Hypnotics, Sedatives, Anticonvulsants, and Anxiolytics (2000) (1)
- Biochemical and pharmacological characterization of the putative dopamine autoreceptor agonist benzopyranopyridine, CGS 15873A (1989) (1)
- Chapter 2. Anxiolytics, Anticonvulsants and Sedative-Hypnotics (1986) (1)
- 13 Identification of the A 2 Adenosine Receptor Binding Subunit by Photo affinity Crosslinking (1)
- The NMDA antagonists, CPP and CGS 19755, lack affinity for central benzodiazepine receptors. (1988) (1)
- Interactions of taurine and beta-alanine with central nervous system neurotransmitter receptors. (1980) (1)
- Fifty years of Biochemical Pharmacology: the discipline and the journal. (2008) (1)
- Comparison of central gastric antisecretory effects of desmethylimipramine, doxepin and pirenzepine in rats (1984) (1)
- Organizing for drug discovery. (1988) (1)
- BENZQUINAMIDE: A CENTRALLY MEDIATED ANTAGONIST OF HISTAMINE-AND ACETYLCHOLINE-INDUCED BRONCHOCONSTRICTION. (1965) (1)
- Enoxaparin After Pancreaticoduodenectomy for Pancreatic Cancer: Prescription Patterns and Outcomes (2022) (1)
- P 2 -Purinoceptors: Advances and therapeutic opportunities (2019) (1)
- Adenosine is an Antiinflammatory Autocoid: Adenosine Receptor Occupancy Promotes Neutrophil Chemotaxis and Inhibits Superoxide Anion Generation (1990) (0)
- Interaction of the component enantiomers of the putative dopamine autoreceptor agonist, TL-99 (6,7-dihydroxy-2-dimethylamino tetralin) with dopaminergic systems in mammalian brain and teleost retina (1983) (0)
- Nucleotides and their receptors in the nervous system. 1-2 August 1998, Leipzig, Germany. (1998) (0)
- Nicotinic Receptors: New Targets for Therapeutic Agents (2006) (0)
- Patent Update Cardiovascular & Renal: Recent progress in modulators of purinergic activity (1995) (0)
- Poster presentations (Abstracts) (2006) (0)
- Gastric antisecretory and pharmacologic properties of N,N-dimethyl-N'-(2-diisopropylaminoethyl)-N-(4,6-dimethyl-2-pyridyl)ur ea (L-634,366). (1986) (0)
- Functional Roles of A1 and A2 Receptors in Rat Hippocampus and Striatum (1990) (0)
- P2 Purine and Pyrimidine Receptors: Emerging Superfamilies of G- Protein-Coupled and Ligand-Gated Ion Channel Receptors (2010) (0)
- Perspectives in Pharmacology Challenges in the Search for Drugs to Treat Central Nervous System Disorders (2009) (0)
- Assessment of the chloroethyl analog of 3-PPP (N-n-propyl-3-(3-hydroxyphenyl)-piperidine), 3-PPP-C1 as an irreversible ligand for central dopaminergic recognition sites. (1983) (0)
- The Design of a Series of Highly A2 Selective Adenosine Agonists (1990) (0)
- Receptors as Drug Targets (1998) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With M Williams?
M Williams is affiliated with the following schools:
